CORE--SOLID TUMOR PHARMACOLOGY

核心--实体瘤药理学

• 批准号: 6500723
• 负责人: CLINTON F STEWART
• 金额: $ 28.58万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6500723
• 关键词: DNA topoisomerases; antineoplastics; bioassay; biomedical facility; enzyme linked immunosorbent assay; high performance liquid chromatography; histology; microdialysis; neoplasm /cancer pharmacology; pediatric neoplasm /cancer; pharmacokinetics; topotecan; western blottings

The functions of the Solid Tumor Pharmacology Core are to: A. Perform assays to quantitate drug and drug metabolite concentrations in biological specimens collected from animals and patients as part of preclinical and clinical pharmacokinetic studies within this Program. B. Perform additional special laboratory procedures as required to support the projects included in this Program. C. Perform appropriate biochemical assays (e.g., immunoblot analysis for topoisomerase I, catalytic activity of topoisomerase I) on preclinical and clinical samples to evaluate the activity of anticancer drugs to provide more comprehensive pharmacodynamic analyses. D. Maintain computer databases of data from analyses performed in the Solid Tumor Pharmacology Core, and generate data retrievals and reports as required. E. Analyze pharmacokinetic data obtained from preclinical and clinical pharmacokinetic studies, and fit appropriate pharmacokinetic and pharmacodynamic models to the data, as requested by investigators in this Program.

实体瘤药理学核心的功能是：